H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Coherus Biosciences to $20 from $24 and keeps a Buy rating on the shares post the Q2 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- 3 Best Stocks to Buy Now, 8/3/2023, According to Top Analysts
- Coherus Biosciences reports Q2 EPS 49c, consensus 44c
- Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 7/25/2023, According to Top Analysts